Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 2/2010

01-06-2010 | Clinical Trial Report

Iron in Heart Failure: Friend or Foe?

Authors: Qurat-ul-ain Jelani, Stuart D. Katz

Published in: Current Heart Failure Reports | Issue 2/2010

Login to get access

Excerpt

Anker SD, Comin Colet J, Filippatos G, et al.: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009, 361:2436–2448. …
Literature
1.
Eaton JW, Qian M: Molecular bases of cellular iron toxicity. Free Radic Biol Med 2002, 32:833–840.CrossRefPubMed
2.
3.
Tang YD, Katz SD: Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006, 113:2454–2461.CrossRefPubMed
4.
Auerbach M, Ballard H, Glaspy J: Clinical update: intravenous iron for anaemia. Lancet 2007, 369:1502–1504.CrossRefPubMed
5.
Mancini DM, Katz SD, Lang CC, et al.: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003, 107:294–299.CrossRefPubMed
6.
Rouault TA, Tong WH: Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol 2005, 6:345–351.CrossRefPubMed
7.
Beard JL: Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001, 131:568S–579S; discussion 580S.PubMed
8.
Besarab A, Bolton WK, Browne JK, et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584–590.CrossRefPubMed
9.
Araujo JA, Romano EL, Brito BE, et al.: Iron overload augments the development of atherosclerotic lesions in rabbits. Arterioscler Thromb Vasc Biol 1995, 15:1172–1180.PubMed
10.
Zheng H, Cable R, Spencer B, et al.: Iron stores and vascular function in voluntary blood donors. Arterioscler Thromb Vasc Biol 2005, 25:1577–1583.CrossRefPubMed
Metadata
Title
Iron in Heart Failure: Friend or Foe?
Authors
Qurat-ul-ain Jelani
Stuart D. Katz
Publication date
01-06-2010
Publisher
Current Science Inc.
Published in
Current Heart Failure Reports / Issue 2/2010
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-010-0012-x

Other articles of this Issue 2/2010

Current Heart Failure Reports 2/2010 Go to the issue

ReviewPaper

Pharmacoepigenetics in Heart Failure

ReviewPaper

Relaxin: Review of Biology and Potential Role in Treating Heart Failure

ReviewPaper

Testosterone Deficiency and Exercise Intolerance in Heart Failure: Treatment Implications

ReviewPaper

Venous Congestion and Endothelial Cell Activation in Acute Decompensated Heart Failure

ReviewPaper

Electrical Muscle Stimulation for Chronic Heart Failure: An Alternative Tool for Exercise Training?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits